Multistate fungal meningitis outbreak -- interim guidance for treatment.
CDC and the Food and Drug Administration (FDA) continue to work closely with state and local public health departments on the multistate meningitis outbreak investigation of fungal infections among patients who received a steroid injection of a potentially contaminated product into the spinal area. The investigation also includes possible fungal infections associated with injections in a peripheral joint space. These cases are associated with a potentially contaminated steroid medication prepared by New England Compounding Center (NECC) in Framingham, Massachusetts.
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D004339:Drug Compounding; D004340:Drug Contamination; D006801:Humans; D007270:Injections, Intra-Articular; D016921:Meningitis, Fungal / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D010594:Pharmacies; D017410:Practice Guidelines as Topic; D013256:Steroids / Q000008:administration & dosage / Q000009:adverse effects; D014481:United States / Q000453:epidemiology
D000935:Antifungal Agents; D013256:Steroids